| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SGLT2 |
| Uniprot No | P31639 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 228-277aa |
| 氨基酸序列 | GLFDKYLGAATSLTVSEDPAVGNISSFCYRPRPDSYHLLRHPVTGDLPWP |
| 预测分子量 | 31 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于SGLT2(钠-葡萄糖协同转运蛋白2)重组蛋白研究的代表性文献概述(注：文献名为虚构示例，实际引用需核实原始论文)：
1. **文献名称**: "Crystal structure of human SGLT2 reveals key residues for glucose transport"
**作者**: Wright EM et al.
**摘要**: 本研究首次解析了重组表达的人源SGLT2蛋白的晶体结构，揭示了其跨膜结构域中葡萄糖结合位点的关键氨基酸残基，阐明了钠离子与葡萄糖协同转运的分子机制，为抑制剂设计提供结构基础。
2. **文献名称**: "Functional characterization of recombinant SGLT2 in mammalian cell lines"
**作者**: Ehrenkranz JRL et al.
**摘要**: 通过在HEK293细胞中重组表达SGLT2蛋白，验证其葡萄糖转运活性及动力学参数，发现其最大转运速率(Vmax)与生理浓度下的葡萄糖亲和力，证实了重组蛋白在体外药物筛选模型中的应用潜力。
3. **文献名称**: "SGLT2 inhibitors: Structural optimization based on recombinant protein binding assays"
**作者**: Inagaki N et al.
**摘要**: 利用重组SGLT2蛋白进行高通量药物筛选，分析达格列净等抑制剂的结合模式，发现C-芳基葡萄糖苷结构域的疏水相互作用是抑制活性的关键，推动第二代SGLT2抑制剂的开发。
**提示**：实际文献检索建议通过PubMed或SciFinder使用关键词"SGLT2 recombinant protein structure/expression/inhibitor"查询，重点参考《Nature》《Diabetes Care》等期刊的论文。部分经典研究可能来自：
- Wright EM团队(SGLT结构生物学)
- Ferrannini E(SGLT2生理功能)
- 日本制药企业(抑制剂开发研究)
**Background of SGLT2 Recombinant Protein**
Sodium-glucose cotransporter 2 (SGLT2) is a membrane protein primarily expressed in the proximal tubules of the kidneys, where it facilitates glucose reabsorption by coupling glucose transport with sodium ions. It plays a critical role in maintaining glucose homeostasis, reabsorbing ~90% of filtered glucose under normal physiological conditions. Dysregulation of SGLT2 is linked to hyperglycemia in type 2 diabetes, making it a key therapeutic target.
Recombinant SGLT2 protein is engineered through genetic cloning and expression in heterologous systems (e.g., mammalian or insect cells) to produce functional, purified protein for research and drug development. This recombinant form retains the structural and functional characteristics of native SGLT2. enabling studies on its kinetics, inhibitor interactions, and molecular mechanisms.
The development of SGLT2 recombinant protein has accelerated the discovery of SGLT2 inhibitors, a class of antidiabetic drugs (e.g., empagliflozin, dapagliflozin) that block renal glucose reabsorption, promoting urinary glucose excretion and lowering blood sugar levels. Beyond therapeutics, recombinant SGLT2 is utilized in structural biology (e.g., X-ray crystallography, cryo-EM) to resolve its 3D conformation, aiding in rational drug design.
Challenges in SGLT2 recombinant production include ensuring proper post-translational modifications (e.g., glycosylation) and membrane localization, which are critical for functionality. Advances in expression systems and purification techniques continue to enhance its application in high-throughput screening and mechanistic studies. Overall, SGLT2 recombinant protein serves as a vital tool in diabetes research and the development of next-generation metabolic therapies.
×
